Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Streptococcus pneumoniae

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    189 result(s) found for: Streptococcus pneumoniae. Displaying page 4 of 10.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-001496-36 Sponsor Protocol Number: AMPISUL/AMOXICLAV-HD_V1.4 Start Date*: 2013-07-19
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Innere Medizin I, Klinische abteilung für Infektionen und Tropenme
    Full Title: Multiple-dose pharmacokinetics of ampicillin / sulbactam and amoxicillin / clavulanic acid during haemodialysis in longterm haemodialysis patients
    Medical condition: Suspected or proven bacterial infection requiring therapy with broad spectrum antibiotics
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10042196 Streptococcus pneumoniae secondary bacterial infection of acute bronchitis LLT
    14.1 10021881 - Infections and infestations 10053021 Gram-positive bacterial infection LLT
    14.1 10021881 - Infections and infestations 10035649 Pneumococcal secondary bacterial infection of acute bronchitis LLT
    14.1 10021881 - Infections and infestations 10004038 Bacterial infection due to streptococcus, group C LLT
    14.1 10021881 - Infections and infestations 10004039 Bacterial infection due to streptococcus, group D LLT
    16.0 10021881 - Infections and infestations 10004031 Bacterial infection due to other gram-negative organisms LLT
    14.1 10021881 - Infections and infestations 10004047 Bacterial infections NEC HLT
    14.1 10021881 - Infections and infestations 10060945 Bacterial infection PT
    14.1 10021881 - Infections and infestations 10004042 Bacterial infection due to unspecified streptococcus LLT
    14.1 10021881 - Infections and infestations 10004037 Bacterial infection due to streptococcus, group B LLT
    14.1 10021881 - Infections and infestations 10054278 Bacterial infection due to streptococcus, group F LLT
    14.1 10021881 - Infections and infestations 10004041 Bacterial infection due to unspecified staphylococcus LLT
    14.1 10021881 - Infections and infestations 10004036 Bacterial infection due to streptococcus, group A LLT
    14.1 10021881 - Infections and infestations 10004044 Bacterial infection NOS LLT
    14.1 10021881 - Infections and infestations 10004035 Bacterial infection due to staphylococcus aureus LLT
    14.1 10021881 - Infections and infestations 10004040 Bacterial infection due to streptococcus, group G LLT
    14.1 10021881 - Infections and infestations 10018657 Gram-negative bacterial infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004953-14 Sponsor Protocol Number: B1851015 Start Date*: 2015-04-09
    Sponsor Name:Pfizer, Inc.
    Full Title: A Phase 3, Randomized, Active-Controlled Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 7-Valent Pneumococcal Conjugate ...
    Medical condition: Pneumococcal Infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001117-25 Sponsor Protocol Number: V114-008 Start Date*: 2017-04-07
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Infants
    Medical condition: Prevention of pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) ES (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2022-000258-27 Sponsor Protocol Number: V116-003 Start Date*: 2022-08-01
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults
    Medical condition: Pneumococcal infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10035644 Pneumococcal infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001909-32 Sponsor Protocol Number: V114-018 Start Date*: 2018-07-31
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eigh...
    Medical condition: Pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001151-12 Sponsor Protocol Number: V114-027 Start Date*: 2018-11-07
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-D...
    Medical condition: prevention of pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-001412-30 Sponsor Protocol Number: HMR3647A/4020 Start Date*: 2005-12-02
    Sponsor Name:Laboratoire Aventis
    Full Title: An open-label, randomized, multicenter, clinical study to compare the effects of telithromycin, azithromycin and cefuroxime axetil on the penicillin or macrolide resistance of Streptococcus pneumon...
    Medical condition: Patients with acute exacerbation of chronic bronchitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-001118-24 Sponsor Protocol Number: 117276 Start Date*: 2014-08-19
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, placebo-controlled, observer-blind, randomised, multi-centre study to describe the immunogenicity and safety of GSK Biologicals’ Quadrivalent Split Virion Influenza Vaccine 2014/2015 I...
    Medical condition: The target population for this study is adults in stable health ≥ 50 years of age at risk for complications of influenza and pneumococcal diseases.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10022005 Influenza viral infections HLT
    17.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-001785-35 Sponsor Protocol Number: V116-010 Start Date*: 2022-11-07
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Ag...
    Medical condition: Pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10035644 Pneumococcal infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006710-36 Sponsor Protocol Number: V116-007 Start Date*: 2022-08-29
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator- Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults Living With HIV
    Medical condition: Pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10035644 Pneumococcal infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-002789-12 Sponsor Protocol Number: U05-PnPS-403 Start Date*: 2005-09-28
    Sponsor Name:Sanofi Pasteur MSD S.N.C
    Full Title: A double blind comparative and randomised study in healthy adults of the safety, tolerability, and immunogenicity of PNEUMOVAX®II formulated with either all new process polysaccharides or all curre...
    Medical condition: Prevention of invasive pneumococcal disease (IPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-023971-25 Sponsor Protocol Number: P100105 Start Date*: 2013-02-05
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014315-12 Sponsor Protocol Number: LIS143 Start Date*: 2010-04-08
    Sponsor Name:CIB/RIVM
    Full Title: Immunogenicity of alternate and reduced immunization schedules using the regular thirteen-valent polysaccharide conjugate vaccine against infection with Streptococcus pneumoniae
    Medical condition: Immunogenicity of alternate and reduced immunization schedules using the regular thirteen-valent polysaccharide conjugate vaccine against infection with Streptococcus pneumoniae
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-004056-36 Sponsor Protocol Number: Sched2 Start Date*: 2007-12-20
    Sponsor Name:Health Protection Agency
    Full Title: A Phase IV, randomised study to evaluate the immune response of UK infants receiving DTaP/Hib/IPV, meningococcal C conjugate and pneumococcal conjugate vaccines, antibody persistence and responses ...
    Medical condition: All products arre vaccines and are given to healthy volunteers to induce immunological responses to provide protection against: Pediacel - tetanus, diphtheria, polio, pertussis (whooping cough), H...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027274 Meningococcal infection PT
    9.1 10061353 Pneumococcal infection LLT
    9.1 10013023 Diphtheria LLT
    9.1 10043376 Tetanus LLT
    9.1 10034738 Pertussis LLT
    9.1 10018955 Haemophilus meningitis LLT
    9.1 10036008 Polio LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001152-35 Sponsor Protocol Number: V114-023 Start Date*: 2019-05-10
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children with Sickle Cell Disease (PNEU–SICKLE)
    Medical condition: Pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004109-21 Sponsor Protocol Number: V114-029 Start Date*: 2021-06-10
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants (PNEU-PED)
    Medical condition: Prevention of pneumococcal disease associated with serotypes included in the vaccine.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-003788-70 Sponsor Protocol Number: V114-026 Start Date*: 2019-07-15
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Phase 3, Multicenter, Randomized, Double-blind, Active-comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-E...
    Medical condition: Pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) NO (Completed) DK (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000944-13 Sponsor Protocol Number: GEN-004-002 Start Date*: 2014-07-30
    Sponsor Name:Genocea Biosciences, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GEN-004, a Pneumococcal Protein Subunit Vaccine, on Colonization Following Intran...
    Medical condition: Pneumococcal Nasal Carriage
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10069594 Pneumococcal immunization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001529-41 Sponsor Protocol Number: 0887X1-4596 Start Date*: 2017-06-02
    Sponsor Name:Pfizer Inc.
    Full Title: Prevenar Post-Licensure Safety Study in Russia: Frequency Of Fever Post Vaccination
    Medical condition: Infants from 3 months up to 23 months of age who may benefit from active immunization against disease caused by Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (including sepsis...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-012701-19 Sponsor Protocol Number: 113171 Start Date*: 2009-10-15
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomized, controlled, observer-blind study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Streptococcus pneumoniae protein containing va...
    Medical condition: Two-dose primary vaccination of healthy children between 12 and 23 months of age at the time of the first vaccination against Streptococcus pneumoniae (S pneumoniae) and Haemophilus influenzae (H. ...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 14 16:35:13 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA